To compare the effects of intravenous heparin with those of oral aspirin on acute ischemic stroke progression.
- Aspirin (acute stroke) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Heparin (acute stroke) Drug
Intervention Desc: Intravenous anticoagulant.
Multi-center, prospective, single-blinded, randomized, controlled study.
Eligible patients received a complete diagnostic workup for stroke, including MRI and MRA, and were randomized into either a heparin-treatment group or an aspirin-treatment group. The heparin group received intravenous heparin, titrated according to activated partial thromboplastin time (aPTT) for 6 days. At that point, the heparin was discontinued, and the patients received aspirin 300 mg/day for the rest of the study. Patients in the aspirin group received aspirin 300 mg/day throughout the study period. All patients had their NIHSS score evaluated daily for 1 week, and again at 2 weeks. MRS and BI scores were assessed at 1 and 3 months.
|Type||Measure||Time Frame||Safety Issue|
|Primary||National Institute of Health Stroke Scale (NIHSS) score at 1 week, relative to baseline NIHSS score.|
|Secondary||Barthel Index (BI) and Modified Rankin Scale (MRS) at 3 months.|